Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?

NCT06758830 is registered in ClinicalTrials.gov with National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos as lead sponsor.

NCT NCT06758830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06758830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?
Lead sponsor
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 6, 2025
Completion date
December 27, 2029
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiotherapy, chemotherapy, chemotherapy side effects, low anterior resection syndrome, neoadjuvant therapy, organ preservation, quality of life, radiotherapy, radiotherapy side effect, rectal cancer, total neoadjuvant treatment